The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human phase I/Ib multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026 in patients with metastatic breast cancer with expansion in metastatic triple negative breast cancer.
 
Muralidhar Beeram
Honoraria - Genentech (Inst); Johnson & Johnson (Inst)
Consulting or Advisory Role - Novartis (I)
Speakers' Bureau - Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst)
Research Funding - Lilly (Inst); Mersana (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Genentech; Merck
 
Judy Sing-Zan Wang
Speakers' Bureau - AstraZeneca
Research Funding - Acerta Pharma/AstraZeneca (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); Birdie (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); CicloMed (Inst); Clovis Oncology (Inst); Curis (Inst); cyteir (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); Ignyta (Inst); Incyte (Inst); Jacobio (Inst); Janssen Research & Development (Inst); Jounce Therapeutics (Inst); Jounce Therapeutics (Inst); Klus Pharma (Inst); Kyocera (Inst); Lilly (Inst); Loxo (Inst); LSK BioPharma (Inst); Lycera (Inst); Lycera (Inst); Macrogenics (Inst); Merck (Inst); Millenium Pharamceuticals (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Phoenix Pharmaceuticals (Inst); Placon (Inst); Portola Pharmaceuticals (Inst); Prelude Therapeutics (Inst); QiLu Pharmaceutical (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Stemline Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); TopAlliance BioSciences Inc (Inst); Vedanta Biosciences (Inst); Verastem (Inst); Vigeo Therapeutics (Inst); Xencor (Inst)
 
Lida A. Mina
No Relationships to Disclose
 
Amita Patnaik
Honoraria - Texas Society of Clinical Oncology (TxSCO)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb (I); Genentech/Roche (I); Merck; MERCK (I); Novartis; Seagen; Silverback Therapeutics
Research Funding - Abbvie (Inst); Arcus Ventures (Inst); Astellas Pharma (Inst); Corvus Pharmaceuticals (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fochon Pharmaceuticals (Inst); Forty Seven (Inst); Infinity Pharmaceuticals (Inst); Klus Pharma (Inst); Lilly (Inst); Livzon (Inst); Merck (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Plexxikon (Inst); Surface Oncology (Inst); Symphogen (Inst); Syndax (Inst); Tesaro (Inst); Upsher-Smith (Inst); Vigeo Therapeutics (Inst)
 
Mary Rose Pambid
No Relationships to Disclose
 
Aarthi Jayanthan
No Relationships to Disclose
 
My-my Huynh
No Relationships to Disclose
 
Sandra Elaine Dunn
No Relationships to Disclose
 
Gerrit Los
No Relationships to Disclose
 
Andrew Dorr
Consulting or Advisory Role - BrightPath Biotheraputics; Curegenix; Fortis; Orphagen Pharmaceuticals; Phoenix Molecular Designs; Tyra Biosciences; Vivace Therapeutics